Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Overview of Graft-Versus-Host Disease

April 13th 2021

Corey S. Cutler, MD, MPH, FRCPC; Yi-Bin Chen, MD; and Haris Ali, MD, provide insight on the nature of graft-vs-host disease (GVHD) and common risk factors for acute and chronic GVHD.

FDA Approval Insights: Umbralisib in Marginal Zone Lymphoma and Follicular Lymphoma

April 12th 2021

Dr. Fowler discusses the data that served as the basis for the accelerated approval of umbralisib in marginal zone lymphoma and follicular lymphoma, the implications of the regulatory decision on clinical practice, and potential next steps for the PI3Kδ and CK1ε inhibitor.

CAR T-Cell Therapy for R/R Follicular Lymphoma

April 12th 2021

Implications for adding CAR T-cell therapy to the treatment armamentarium for relapsed/refractory follicular lymphoma in the near future.

AMG 176/Gilteritinib Combo Shows Preclinical Activity in FLT3-ITD+ AML

April 12th 2021

The combination of the selective MCL-1 inhibitor AMG 176 plus gilteritinib was found to synergistically target preclinical models of FLT3 internal tandem duplication–mutated acute myeloid leukemia.

ZUMA-5 in R/R Follicular Lymphoma

April 12th 2021

Caron A. Jacobson, MD, MMSc, of Dana-Farber Cancer Institute, comments on current data demonstrated by the ZUMA-5 trial in relapsed/refractory follicular lymphoma and the potential use of CAR T-cell therapy moving forward.

Parsaclisib/Ruxolitinib Improves SVR and Symptom Burden in Myelofibrosis

April 11th 2021

The combination of parsaclisib and ruxolitinib has resulted in the improvement of spleen volume reduction and symptom burden in patients with myelofibrosis who have previously experienced a suboptimal response to a standard dose of single-agent ruxolitinib.

Copanlisib/Rituximab Improves PFS in Relapsed Indolent Non-Hodgkin Lymphoma

April 10th 2021

The combination of copanlisib and rituximab was associated with a 48% reduction in the risk of disease progression or death compared with rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.

Voruciclib Alone, Plus Sotorasib or Adagrasib, Shows Preliminary Potency Against KRAS+ Cancers

April 10th 2021

The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers when used in combination with sotorasib and adagrasib in preclinical models.

Challenges of Accurate Diagnosis of TA-TMA After Hematopoietic Stem Cell Transplant

April 8th 2021

A panel of experts recall the challenges of accurate early detection of transplant-associated thrombotic microangiopathy and its importance for improved patient outcomes.

Novel Agents Expand MDS Treatment Armamentarium After Years of Inactivity

April 8th 2021

Amit K. Verma, MD, spotlights new agents that have entered the myelodysplastic syndrome treatment arsenal and novel combinations currently under exploration, as well as efforts that are showing promise in patients with acute myeloid leukemia.

Relationship Between TA-TMA Development and GVHD

April 8th 2021

The panel considers the development, morbidity, and survival of transplant-associated thrombotic microangiopathy associated with GVHD (graft-versus-host disease).

Weight-Based Dosing With Narsoplimab Is Recommended in HSCT-TMA

April 7th 2021

Pharmacodynamic and pharmacokinetic modeling of the investigational MASP-2 inhibitor narsoplimab supported a weight-based dosing method for patients with hematopoietic stem cell transplant–associated thrombotic microangiopathy.

Selinexor, Bortezomib, and Dexamethasone Combination Proves Effective for Myeloma

April 7th 2021

In December 2020, the FDA approved selinexor in combination with the proteasome inhibitor bortezomib and dexamethasone for patients with MM who have received at least 1 prior therapy.

A Review of Pacritinib and PACIFICA Data

April 7th 2021

Srdan Verstovsek, MD, PhD, briefly reviews the role of pacritinib in patients with myelofibrosis as well as the PACIFICA study.

Mitigating Peripheral Neuropathy Is Still Focus of Ongoing Research in Hodgkin Lymphoma

April 7th 2021

Mendel Goldfinger, MD, discusses some of the key points of the ECHELON-1 trial data.

Using Second-Generation FLT3 Inhibitors in R/R AML

April 7th 2021

Jessica K. Altman, MD, reviews the safety and efficacy of gilteritinib as seen in the ADMIRAL trial for the treatment of relapsed/refractory acute myeloid leukemia.

Testing for FLT3 During Relapse in AML

April 7th 2021

Leukemia experts discuss the role of genetic testing to check for FLT3 mutations at the time of relapse in acute myeloid leukemia.

The Role of Transplant in Myelofibrosis

April 7th 2021

Experts discuss the role of transplant and evaluating options in patients with myelofibrosis.

Searching for Molecular Targets in Myeloid Malignancies and Beyond

April 6th 2021

Ulrich Steidl, MD, PhD, discusses translational research efforts that have been made with targeting leukemia stem cells and ongoing clinical trials that are examining novel therapeutic targets in myeloid malignancies and beyond.

D-VCd Rises as the New Standard of Care in Newly Diagnosed AL Amyloidosis

April 6th 2021

Jonathan L. Kaufman, MD, discusses the significance of subcutaneous D-VCd in the treatment of patients with AL amyloidosis, remaining questions with the approach, and emerging strategies for those with high-risk cardiac features.